Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity
about
Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimensAdvances in genetics: widening our understanding of prostate cancerNew challenges for BRCA testing: a view from the diagnostic laboratoryWhole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Accuracy of Molecular Data Generated with FFPE Biospecimens: Lessons from the LiteratureGenome-wide nucleosome map and cytosine methylation levels of an ancient human genomeFixing Formalin: A Method to Recover Genomic-Scale DNA Sequence Data from Formalin-Fixed Museum Specimens Using High-Throughput SequencingDetecting ultralow-frequency mutations by Duplex Sequencing.Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology.Non-invasive analysis of intestinal development in preterm and term infants using RNA-Sequencing.The role of replicates for error mitigation in next-generation sequencing.Reporting tumor molecular heterogeneity in histopathological diagnosis.Formalin fixation in the '-omics' era: a primer for the surgeon-scientist.Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis.Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens.Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnosticsMassively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy.Personalized genomic analyses for cancer mutation discovery and interpretation.Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples.Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue.Organocatalytic removal of formaldehyde adducts from RNA and DNA basesWhole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue SamplesRobust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples.The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencingSingle-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNAUltra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signatureComparing mutation calls in fixed tumour samples between the affymetrix OncoScan® array and PCR based next-generation sequencing.Targeted sequencing of both DNA strands barcoded and captured individually by RNA probes to identify genome-wide ultra-rare mutations.Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples.A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.Biobanking in genomic medicine.Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.Next generation sequencing and a new era of medicine.
P2860
Q24622594-4CE3596D-A623-411E-826C-FDBF3FDC1D6BQ26740628-2BB1A486-ECE8-4409-AE4B-ECB380A900C5Q26741855-5080F45F-F4D1-4D47-AD8B-47499DDAE2E8Q27853005-A975C9D6-10EF-4AB6-B52D-D02DA46B599AQ28084521-E96DB14B-5CB2-4E8D-B042-140FE81A824EQ28658266-D78EF197-CEDE-404D-A900-87B7C73EA435Q30000009-05FA36D4-E366-4BD5-9623-EB0A1A6D9D03Q30413211-F4D69F41-AF0B-4CAE-91C6-019C911236F5Q30874026-886D86E1-98FA-44F6-9873-0D821CC1A71BQ31077769-35168417-B406-42DA-9920-EDC38DEED1A1Q33807980-7D37D94D-E39A-4988-AAD0-9B782864BA58Q33921022-665647CF-8EEF-4386-B65C-7665FE5051EAQ34050798-C577C3A6-2B85-445B-B536-70582E3E9BECQ34263623-12AB1E0E-DD62-40A5-82CA-F926D6B9FDDEQ34560270-3CFDEB40-44D3-4B3D-9D22-2E27042BF402Q34659939-CA3189EC-0AFA-4B5D-A665-7B8581C6D5A2Q34786722-B2E4A146-F79A-460B-861A-C5CCC4003424Q35032007-F1E5BE94-C69B-4308-81E0-711E72CADE4BQ35176679-551EA86F-03D8-4CDD-86DC-689A0F690903Q35178113-8F6488DA-FD4B-4CEF-BEEE-B69D90009EB2Q35221918-F521DBB8-5821-4F77-8A8A-8463BBA24EBBQ35497448-FA637470-52C6-4708-AE68-91263E2FF7ACQ35602861-56DA3ABE-105C-4B85-915E-DBBEBB5BD719Q35641264-7E2CB9AB-6FCE-49A2-A8A6-C643929A25F5Q35722718-4DD86E14-7474-447C-8306-E8E9C5C334B5Q35751384-A76FCFFC-0F65-4A9D-90AB-286CE796C78CQ35831238-2ADC1E5D-723B-46D4-B537-640839C622BBQ35862252-981A4425-B60E-4B2C-A159-3AD75DB06039Q35881001-755D47EC-665B-413F-9443-ACCD285E0976Q36028346-E2D45505-7DB3-4D11-965B-CEC185508049Q36087015-F07BED41-99C7-4FB7-BAA8-DC7FB51377FDQ36210809-F6A9C03A-210A-4E5C-9082-4DEE912D2C89Q36313666-2ECEAC6A-5628-4E77-B75A-C5BAD6A196E8Q36404734-AD8AD88A-5CC7-416A-A5BD-007A656A12FAQ36627211-55EC2E66-D0CB-436C-903E-DB32F760FBA5Q36645600-3A7138D2-4A7E-46C5-BB57-E36F2EE71183Q36857291-A8C50804-6F96-441E-BC47-497B35A72631Q36902969-8BF10267-297F-4955-95DC-603DA21AC064Q37389151-F018BD54-B36F-415F-B25A-D532819F44E5Q37409165-0AD367E1-8CBF-4EF6-9FF9-CD9CE6A18C47
P2860
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Targeted high throughput seque ...... amount and tumor heterogeneity
@ast
Targeted high throughput seque ...... amount and tumor heterogeneity
@en
Targeted high throughput seque ...... amount and tumor heterogeneity
@nl
type
label
Targeted high throughput seque ...... amount and tumor heterogeneity
@ast
Targeted high throughput seque ...... amount and tumor heterogeneity
@en
Targeted high throughput seque ...... amount and tumor heterogeneity
@nl
prefLabel
Targeted high throughput seque ...... amount and tumor heterogeneity
@ast
Targeted high throughput seque ...... amount and tumor heterogeneity
@en
Targeted high throughput seque ...... amount and tumor heterogeneity
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeted high throughput seque ...... amount and tumor heterogeneity
@en
P2093
Bernd Timmermann
Georg Bartsch
Georg Schaefer
Helmut Klocker
Irmgard Verdorfer
Melanie Isau
Michal R Schweiger
Sylvia Krobitsch
P2860
P2888
P356
10.1186/1755-8794-4-68
P577
2011-09-29T00:00:00Z
P5875
P6179
1012358604